Research programme: cancer therapeutics - OncoMed

Drug Profile

Research programme: cancer therapeutics - OncoMed

Alternative Names: Anti-cancer stem cell monoclonal antibodies - OncoMed; Anti-CSC monoclonal antibodies - OncoMed; Anti-tumour-initiating cell monoclonal antibodies - OncoMed; GITRL-Fc; GITRL-Fc trimer - OncoMed; I/O#2; IO#2; IO#3; OMP-336B11; OMP-OMP-336B11

Latest Information Update: 12 Apr 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OncoMed Pharmaceuticals
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action DLL4 protein inhibitors; TNFRSF18 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 02 Aug 2017 OncoMed plans a phase I trial for OMP 336B11 in second half of 2017
  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 05 Jan 2017 OncoMed plans to file an IND application with the US FDA for OMP 336B11 in Cancer in the first half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top